Literature DB >> 10623803

Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions.

S V Jalukar1, B S Hostager, G A Bishop.   

Abstract

Signaling through CD40 in B cells leads to B cell proliferation, Ig and IL-6 secretion, isotype switching, and up-regulation of surface molecules. TNF receptor-associated factor (TRAF) proteins associate with the cytoplasmic tail of CD40 and act as adapter molecules. Of the six TRAFs identified to date, TRAFs 2, 3, 5, and 6 are reported to associate directly with the cytoplasmic tail of CD40, but previous studies have principally examined transient overexpression of TRAF6 in cells that do not normally express CD40. Thus, we examined the role of TRAF6 in CD40-mediated B lymphocyte effector functions using two approaches. We produced and stably expressed in mouse B cell lines a human CD40 molecule with two cytoplasmic domain point mutations (hCD40EEAA); this mutant fails to bind TRAF6, while showing normal association with TRAFs 2 and 3. We also inducibly expressed in B cells a transfected "dominant-negative" TRAF6 molecule which contains only the C-terminal TRAF-binding domain of TRAF6. Using both molecules, we found that TRAF6 association with CD40 is important for CD40-induced IL-6 and Ig secretion, and that TRAF6 mediates its effects on CD40-stimulated Ig secretion principally through its effects on IL-6 production by the B cell. TRAF6 association with CD40 was also found to be important for B7-1 up-regulation, but not for up-regulation of other surface molecules. Interestingly, however, although we could show TRAF6-dependent CD40-mediated activation of NF-kappaB in 293 kidney epithelial cells, no such effect was seen in B cells, suggesting that TRAF6 has cell-type-specific functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623803     DOI: 10.4049/jimmunol.164.2.623

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

2.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

3.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

Review 4.  Roles of TRAF6 in CD40 signaling.

Authors:  Bruce S Hostager
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

5.  Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling.

Authors:  Anna L Peters; Gail A Bishop
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

Review 6.  Roles of TRAF molecules in B lymphocyte function.

Authors:  Ping Xie; Zachary J Kraus; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-21       Impact factor: 7.638

7.  CD40 and tumour necrosis factor-α co-operate to up-regulate inducuble nitric oxide synthase expression in macrophages.

Authors:  Jose-Andres C Portillo; Luis Muniz Feliciano; Genevieve Okenka; Frederick Heinzel; M Cecilia Subauste; Carlos S Subauste
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

8.  CD40-associated TRAF 6 signaling is required for disease induction in a retrovirus-induced murine immunodeficiency.

Authors:  Kathy A Green; Cory L Ahonen; W James Cook; William R Green
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.

Authors:  Jose-Andres C Portillo; Jennifer A Greene; Isaac Schwartz; Maria Cecilia Subauste; Carlos S Subauste
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

10.  A novel polymorphism of the human CD40 receptor with enhanced function.

Authors:  Anna L Peters; Robert M Plenge; Robert R Graham; David M Altshuler; Kathy L Moser; Patrick M Gaffney; Gail A Bishop
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.